Healthcare
Moderna, Inc.(MRNA)
Live Price
Offline$59.35
-7.22% today
1Y Change
+101.16%
Window
Jun 26, 2025 β Jun 16, 2026
- Market Cap
- $17.99B
- Revenue Growth
- -39.2%
- EPS Growth
- +21.7%
- Dividend Yield
- 0.0%
Coverage: 244 bars Β· Jun 26, 2025 β Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Moderna, Inc. (MRNA) is a Healthcare stock with a market cap of $17.99B and listed on NASDAQ. The stock last traded around $59.34 and up 101.2% across the available one-year price window (Jun 26, 2025 β Jun 16, 2026). Baseline metrics include revenue growth of -39.2%, EPS growth of +21.7%, a dividend yield of 0.0%. What stands out right now is revenue -39.2%, EPS +21.7%, free cash flow +49.1% with operating margin -153.3% and ROIC -37.5%. Valuation already assumes a fairly strong business story at price/sales 8.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MRNA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-39.2% vs +7.6% peer median
Operating Margin
Below sector median
-153.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -39.2% and EPS is at +21.7%, with operating margin around -153.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +8.2% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | β | +12.0% | +3.1% | -2.3% |
2026 Feb 13, 2026 | +16.9% | +4.0% | +19.1% | +26.2% |
2025 Nov 6, 2025 | +72.7% | +0.9% | +2.6% | +13.9% |
Benchmark Edge
MRNA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MRNA
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MRNA Max Drawdown
-35.51%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MRNA and SPY.
Company Overview
Moderna, Inc.
NASDAQ Global Select
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
- Leadership
- StΓ©phane Bancel
- IPO Date
- Dec 7, 2018
- Employees
- 5.8k
- Street Address
- 325 Binney Street
- Mailing
- Cambridge, MA, 02142
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 714 6500
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 8.1
- Price/Book
- 2.4
Growth
- Revenue
- -39.2%
- EPS
- +21.7%
- Free Cash Flow
- +49.1%
Profitability
- Gross Margin
- -13.9%
- Operating Margin
- -153.3%
- Net Margin
- -143.6%
- ROE
- -36.7%
- ROIC
- -37.5%
Balance Sheet
- Debt/Equity
- 0.17
- Current Ratio
- 2.41
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.